3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
2
Unknown
1
Recruiting
1
Sponsor Class
OTHER
131
INDUSTRY
35
OTHER_GOV
6
NIH
4
NETWORK
2
FED
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Lymphoid
1
Conditions
Prostatic Neoplasms
9
Neoplasms
6
Carcinoma, Non-Small-Cell Lung
5
Lung Neoplasms
4
Carcinoma, Hepatocellular
3
Non-Muscle Invasive Bladder Neoplasms
2
Neoplasms by Site
2
Esophageal Squamous Cell Carcinoma
2
Adenocarcinoma Of Esophagus
2
Urogenital Neoplasms
1
Tobacco Use Disorder
1
Tobacco Use
1
Thoracic Neoplasms
1
Substance-Related Disorders
1
Small Cell Lung Carcinoma
1
Respiratory Tract Neoplasms
1
Respiratory Tract Diseases
1
Prostatic Neoplasms, Castration-Resistant
1
Prostatic Diseases
1
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Pain, Postoperative
1
Opioid-Related Disorders
1
Neoplasm Metastasis
1
Motor Activity
1
Male Urogenital Diseases
1
Lymphoma
1
Lung Diseases
1
Liver Neoplasms
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Leukemia
1
Interventions
zanubrutinib
1
venetoclax
1
ibrutinib
1
acalabrutinib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
FED
×
Leukemia
×
Clear all
NCT06520098
2025-10-14
Benefit VA
VA Office of Research and Development
Phase 2
Recruiting
100 enrolled